Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Lol. So you're saying this management team, that is made up of multi-millionaires, gives" shares to outsiders so they can help their friends make a little money and dilute their own shares while they hold. I'm sure Doug Ingram would be okay with that. It's not like he has any other options. And the university is in on it too right? Talk about a brick wall.
Nobody in management sold and these guys aren't in it to help enrich their friends at the expense of the company. Your thesis of insider sales doesn't make sense if management isn't selling. Nobody who invested in private raises has any advantage over the public. They're all in at .40 or more. And nobody at Nemus has pumped this. I wish they would.
Nobody in management sold. Anyone who bought through private raises were in at .40 or more. So who are the insiders that pumped the stock and sold 2 million shares?
Do you have a link that shows insiders sold 2 million shares?
Anyone who buys this stock should only buy an amount they're comfortable losing. If you're worried about .10 or .20 cent moves then you shouldn't be on it. They're either going to raise money in the next few months to give them a one year cushion to move this forward or they're not. The stock will either explode or go to zero based on that. If you're wringing your hands over the lack of news then you should sell.
They are trying. It's a legit group. There's no pumping or insider selling so anyone calling it a scam has an agenda, the question is will they be able to raise about $5 million and keep moving it along to get bought out?I think they can so we'll see.
If you don't like the stock don't buy it. These guys may not be able to execute but it's anything but a scam. Go to the CBDS or CBIS boards for the scams.
Then don't invest. These guys will do what they have to do and that may mean dilution but you won't see any insider sales unless the company makes it.
This disclaimer has been on their filings since they went public and is filed with every public company that will need cash to go to market. Especially in the biotech sector. It's boilerplate where they're stating the obvious.
Nemus has the IP and high quality people involved. If they can execute, it should be worth more than GW and Zynerba. The question is can they raise the cash and get this uplisted or raise enough cash until they get bought out. I think they're going to either joint venture or sell the rights to their MRSA candidate to raise cash to advance their other candidates. I think they get there but it's a risk.
How does this raise cash for Nemus?
What in the filing are you seeing that indicates they're raising $4 million? All I'm seeing is that they will not receive any of the proceeds.
I've known about Nemus since before it went public. They have better IP than GW. I don't think the Nemus guys believe in any cannabis related drug that has to be metabolized through the liver. It's too unstable. They purposely targeted indications that were easier to study and would pass through clinicals faster and more cheaply. They've known for years that their glaucoma drug is better than anything on the market and they're very confident in the neuropathy and MRSA drugs. If all things were equal, Nemus would trade much higher than GW. I also don't think GW can use their epilepsy drug on anything but what it's targeted for. In other words, once a drug is approved, doctors can write a Rx for patients to use it for anything. It just can't be advertised for anything. The GW drug can only be used for what it's approved for. I also don't think they have patent protection but could be wrong.
The correlation between rabbits and humans is very high in these types tests pertaining to the eye. The variation in humans should be 10% at the most but will probably be negligible.
These guys aren't pumpers and it should give you some assurance by looking at who is on their board. They wouldn't be involved in a pump and dump. They have better IP than GW and Zyne so it will come down to if they're able to execute.
Seriously, how is this thing worth 10 cents let alone $4? I don't own it but I own Nemus and follow this and other cannabis stocks. I know what Nemus has and where it's going but this one makes no sense. There's no revenue, no cash and their product doesn't separate them from anyone.
It will have no impact on Nemus. They already have the licensing rights to the patents for the indications they are targeting. It might be bad news for U of M when the contract comes up for renewal in a few years but it's going to take a long time for other researchers to be compliant to meet DEA standards for growing.
I don think anyone wants a suppository unless you need it. Nemus seems to be avoiding anything that has to go through the liver as is Zynerba. They both seem to be concerned about the efficacy of an oral drug which has merit. We'll see how GWPH does with Epidiolex but Sativex isn't very effective. There are better options on the street.
It has been quiet but I would bet they'll be making announcements on an alignment with an investment bank, uplisting and partnerships that will drive up the price. They have more valuable IP than GW and Zynerba it just comes down to execution. I think they will execute with the group they have.
I think they're having issues with the data. Epidiolex is processed through the liver which isn't as effective with cannabanoids.
There are one or two cannabis related pharmaceutical companies that are probably a better risk because of the indications they're targeting and their delivery methods. I think Zynerba is a better risk and Nemus has much better IP. If and when they uplist, the price will explode. That should happen in the second quarter.
You might be right but I'm concerned about the data. A cannabis drug processed through the liver can lead to mixed results from person to person. For that reason, Zynerba and Nemus are intentionally targeting indications and using delivery methods that bypass the liver.
This is a big deal. The translation is basically Nemus has a CBD derivative that is more stable and effective than what GWPH or any other company has. Most likely, it also means that anyone who is using CBD for a pharmaceutical will need to go through Nemus.
Nice Seeking Alpha article out today discussing the Midtown Partners recent research report with a price target of $2.50 per share. It also discusses the strength of their lead glaucoma candidate. Again, I would take what Nemus has in their pipeline over what GWPH and Zynerba have combined. They're sitting on 40 years of cannabis research and development. The quality of the people involved is a good indication of what Nemus has.
By my estimates, I think the shell guys have about 50,000-100,000 shares left so they should be out of their positions in the next week or two. I would imagine management will consider a reverse spilt if they're positive it will be good for shareholders. This is a sharp group and they'll be very cautious. They have a lot they're working on and there should be good news coming out over the next few months that should drive the price up. I would take what Nemus has in their pipeline over what GWPH and Zynerba have combined.
I think you're dead on. I also think good news is coming. The 3 guys driving this know what they're doing.
Nemus may or may not make it but these guys will never do anything bogus. It looks like the shell guys are about done winding down their positions.
There will be news coming out over the next few months that will help with volume and price. Nemus must have something to attract the talent they have.
It's the shell company guys selling blocks. Should shake out in a couple of months and with news coming, shares should climb. $2-$2.50 per share wouldn't surprise me towards the end of the year.
Those 14.8 million shares are part of the $5 million they just raised. It includes warrants that if exercised, will raise another $7.4 million on top of the $5 million. $12.4 million at 84 cents per share on average which is about where the stock is trading now and it gives them the cash to get into Phase 2. Not seeing the issue with it.
I don't think a valuation based on gross revenue works unless you know the costs. I think it's important to know how much they're paying per bottle. I would imagine their pretax profit is at best $2 per bottle. I would also think they're going to have to spend a bundle on marketing. Maybe my approach is wrong but at 5 times pretax earnings, they need to sell 4- 5 million bottles per year for a valuation of $2.50 per share. It seems like the bet here is if can they sell that many bottles. And how quickly they can get there and if they have something proprietary that's a barrier to competition. Looks like a long shot. Am I missing something?
Anyone know how to calculate how many bottles of water they would have to sell per year for the stock to be worth $2.50 per share with the current number of outstanding shares? My guess is about 1 million per month depending what the cost per bottle is.
Not surprised. Look where the money has come from in the recent raises. It looks like the Chairman is the one who got it done. I'm sure he got Ingram on board as well. Murphy is brilliant and the Board is more than qualified to drive this train with him. It's just a matter of time before everyone figures out what Nemus has and where it's going.
Alan-when you speak with Hollister, ask him about the CBD molecule that was quietly announced and the significance of it being water soluble. My understanding is Epidiolex is not and that's pretty critical in any drug taken orally.
Dead on Alan. They raise $5 million with some heavyweights who know more funds will be raised and an up list is coming in April. Zynerba is the comp of what Nemus should trade at when it goes to the NASDAQ and Nemus has a superior pipeline. A year from now, people are going to be shaking their heads they missed this one.
Besides very good management, what do they have? 2 high risk transdermal patents for speculative indications. One of which will most likely be litigated. $20 per share? I'd rather have Nemus at $1 even if it is OTC. Great management, better pipeline and targeted indications.
Thank you for posting. It's clear that Nemus has stronger IP and a valuable relationship. It seems Zynerba is being driven by the strength and track record of it's' CEO.
What's interesting is Zynerba is saying the same thing the Nemus guys are saying. That oral cannabis drugs will have issues. I don't think either group thinks Epidiolex will be particularly effective. Both are staying away from systemic cannabis drugs due to efficacy concerns and the psychological side effects they can cause.
I believe Nemus is eligible to move to Nasdaq on November 1 based on one year of trading and one year of audited financials. If Zynerba trades at what they're hoping for then it's solely based on being on Nasdaq because Nemus has better IP.
The company states they've done animal testing with their glaucoma drug. I thought I read they used mice instead of rabbits which would be unusual. Does anyone know what animals they used for testing?
Nemus tanked because the guys from the shell company are selling their shares from their .01 base position. There's probably another 600,000 shares to go.
Nemus' glaucoma drug is better than anything on the market as well as their delivery system. Their July 7 announcement doesn't really state what they have. It's a water soluble molecule which is critical for a drug to be effective and to mass produce. I don't believe GW's Epidiolex is water soluble. Pay attention to Ingram joining the board and the fact he bought 100,000 shares at $2.50. He's going to have a big role in Nemus and he's very well connected. Their management and advisors are top notch and they know that an oral, systemic drug is very high risk with limited effectiveness and major side effects. Sativex isn't effective and won't be approved in the US and Epidiolex is probably going to have issues. The risk here is their ability to raise money but they will most likely raise what they need. Once they get to Phase I this stock will jump and an early buyout wouldn't be surprising. It's insane that stocks like CBDS have a higher price right now. These companies have nothing and most have management with questionable pasts. Assuming they raise the $5-$10 million they need in the next year, anyone who owns this stock is going to be very happy in a year or two.